Are we close to using Alzheimer blood biomarkers in clinical practice?
Bruno P.Imbimbo1
Simone Lista2
Camillo Imbimbo3
Robert Nisticò4
1.Department of Research & Development,Chiesi Farmaceutici,Parma,Italy2.i+HeALTH Strategic Research Group,Department of Health Sciences,Miguel de Cervantes European University(UEMC),Valladolid,Spain3.Department of Brain and Behavioral Sciences,University of Pavia,Pavia,Italy4.School of Pharmacy,University of Rome"Tor Vergata",Rome,Italy;Laboratory of Pharmacology of Synaptic Plasticity,EBRI Rita Levi-Montalcini Foundation,Rome,Italy
摘要：Alzheimer's disease(AD)is a progressive neurodegenerative disease histologically characterized by the presence of extraneuronal plaques,mainly formed by the 42-aminoacid isoform of amyloid-β(Aβ1-42),and by intraneuronal neurofibrillary tangles,mainly formed by the tau protein and its hyperphosphorylated isoforms(p-tau).
机标关键词：alzheimerclinicalbloodbiomarkersclosepracticeusing
论文发表日期：2024-12-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：3( 2583-2585 )